Table 4.

Significant disease-related predictors of Hsp90 plasma levels in patients with individual subsets of IIM based on bivariate correlations.

	(Spearman’s r; p-value)
Parameter	PM (n=104)	DM (n=104)	CDM (n=42)	IMNM (n=27)
C-reactive protein			0.497; 0.007
Lactate dehydrogenase	0.636; 0.001	0.574; 0.001	0.535; 0.004	0.584; 0.002
Creatine kinase				0.485; 0.014
Aspartate aminotransferase	0.485; 0.001	0.317; 0.001		0.475; 0.019
Alanine aminotransferase	0.234; 0.015		0.395; 0.042
Manual Muscle Testing 8 (MMT-8) total		-0.210; 0.039
Myosits intention to treat activity index (MITAX)	0.223; 0.024			0.504; 0.028
Patient disease global activity (PDGA)	0.258; 0.010	0.244; 0.016
Doctor disease global activity (DGDA)	0.264; 0.008			0.474; 0.040
Pulmonary disease activity		0.232; 0.021
Muscle disease activity	0.247; 0.012
Constitutional disease activity	0.250; 0.011
Myositis damage index (MDI) extent	0.248; 0.025	0.224; 0.049
Myositis damage index (MDI) extended		0.270; 0.017
Current prednisone equivalent dose	0.382; 0.001			0.450; 0.036

CDM, cancer-associated dermatomyositis; DM, dermatomyositis; IIM, idiopathic inflammatory myopathies; IMNM, immune-mediated necrotizing myopathy; PM, polymyositis.